HLS Therapeutics Stock Price, News & Analysis (TSE:HLS) C$3.64 +0.04 (+1.11%) (As of 12/8/2023 ET) Add Compare Share Share Today's RangeC$3.64▼C$3.7650-Day RangeC$3.36▼C$5.2652-Week RangeC$3.34▼C$11.22Volume3,831 shsAverage Volume22,212 shsMarket CapitalizationC$116.73 millionP/E RatioN/ADividend Yield5.49%Price TargetC$10.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider Trades About HLS Therapeutics Stock (TSE:HLS)HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; Vascepa, an icosapent ethyl capsules for cardiovascular disease; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the United States marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.Read More HLS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HLS Stock News HeadlinesNovember 15, 2023 | finance.yahoo.comSome HLS Therapeutics Inc. (TSE:HLS) Analysts Just Made A Major Cut To Next Year's EstimatesNovember 14, 2023 | finance.yahoo.comNew REDUCE-IT® Analyses Show Vascepa® (Icosapent Ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at BaselineDecember 9, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 9, 2023 | marketwatch.comHLS Therapeutics Plans to Buyback Up to 5% of Its SharesNovember 9, 2023 | finance.yahoo.comHLS Therapeutics Announces Q3 Fiscal 2023 Financial Results and Renewal of Normal Course Issuer BidNovember 9, 2023 | markets.businessinsider.comHLS Therapeutics earnings preview: what Wall Street is expectingOctober 2, 2023 | finance.yahoo.comEmergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of DirectorsSeptember 7, 2023 | finance.yahoo.comPositive Signs As Multiple Insiders Buy HLS Therapeutics StockDecember 9, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comAugust 26, 2023 | seekingalpha.comHLTRF HLS Therapeutics Inc.August 23, 2023 | theglobeandmail.comHLS Therapeutics: Top 10 Undervalued Healthcare Sector Stocks on TSX (HLS)August 13, 2023 | markets.businessinsider.comBloom Burton Remains a Buy on HLS Therapeutics Inc (HLS)August 3, 2023 | finance.yahoo.comHLS Therapeutics to Host Q2 Fiscal 2023 Financial Results Conference CallAugust 3, 2023 | msn.comHLS Therapeutics (HLTRF) Price Target Decreased by 12.21% to 11.36July 28, 2023 | markets.businessinsider.comHLS Therapeutics Inc (HLS) Gets a Hold Rating from Raymond JamesJuly 28, 2023 | finance.yahoo.comWith 38% ownership, HLS Therapeutics Inc. (TSE:HLS) has piqued the interest of hedge funds investorsJuly 10, 2023 | markets.businessinsider.comStifel Nicolaus Remains a Buy on HLS Therapeutics Inc (HLS)July 6, 2023 | fool.comHls Therapeutics (TSX: HLS)July 1, 2023 | finance.yahoo.comAthyrium Capital Announces Sale of Shares of HLS TherapeuticsJune 22, 2023 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on HLS Therapeutics Inc (HLS)June 22, 2023 | marketwatch.comHLS Therapeutics Names John Welborn Chairman, Adds Polar Asset Management Candidate to BoardJune 22, 2023 | finance.yahoo.comHLS Therapeutics Announces Updates to its Board of DirectorsJune 19, 2023 | markets.businessinsider.comHLS Therapeutics Inc (HLS) Received its Third Buy in a RowJune 8, 2023 | finance.yahoo.comHLS Therapeutics Announces Agreement with Polar Asset Management Partners and Retirement of Two Directors from the Board of DirectorsJune 8, 2023 | markets.businessinsider.comStifel Nicolaus Thinks HLS Therapeutics Inc’s Stock is Going to RecoverMay 25, 2023 | baystreet.caThis Healthcare Stock Just Hit a 52-Week Low: Is it Time to Buy?May 16, 2023 | theglobeandmail.comClosing Bell: Hls Therapeutics Inc flat on Tuesday (HLS)See More Headlines Receive HLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HLS Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today12/09/2023Next Earnings (Estimated)3/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolTSE:HLS CUSIPN/A CIKN/A Webwww.hlstherapeutics.com Phone647-495-9000FaxN/AEmployees99Year FoundedN/APrice Target and Rating Average Stock Price TargetC$10.50 High Stock Price TargetC$17.50 Low Stock Price TargetC$5.00 Potential Upside/Downside+188.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)C($1.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-28,560,000.00 Net Margins-45.41% Pretax MarginN/A Return on Equity-24.49% Return on Assets-3.58% Debt Debt-to-Equity Ratio89.13 Current Ratio1.72 Quick Ratio1.01 Sales & Book Value Annual SalesC$62.89 million Price / Sales1.86 Cash FlowC$0.24 per share Price / Cash Flow15.22 Book ValueC$3.17 per share Price / Book1.15Miscellaneous Outstanding Shares32,070,000Free FloatN/AMarket CapC$116.73 million OptionableNot Optionable Beta1.05 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Tim Hendrickson M.B.A. (Age 51)Chief Financial Officer Comp: $524.49kDr. Jason A. Gross Pharm.D. (Age 58)Vice President of Scientific Affairs Comp: $351.75kMr. Ryan C. Lennox B.A. (Age 42)J.D., Senior VP of Legal, HR & Compliance and Corporate Secretary Comp: $386.6kMr. Craig Stuart Millian M.B.A. (Age 55)CEO & Director Brian T. WalshSenior Vice President of CommercialMr. David Spence (Age 55)VP & Corporate Controller More ExecutivesKey CompetitorsBioSyentCVE:RXGreen Organic DutchmanTSE:TGODDelta 9 CannabisCVE:NINECardiol TherapeuticsTSE:CRDLOrganigramTSE:OGIView All CompetitorsInsidersCraig MillianBought 5,000 shares on 11/16/2023Total: C$13,000.00 ($2.60/share)Brian Thomas WalshBought 1,000 shares on 11/15/2023Total: C$2,910.00 ($2.91/share)Polar Asset Management Partners Inc.Bought 20,000 shares on 11/10/2023Total: C$86,000.00 ($4.30/share)Tim HendricksonBought 2,500 shares on 5/19/2023Total: C$11,250.00 ($4.50/share)View All Insider Transactions HLS Stock Analysis - Frequently Asked Questions Should I buy or sell HLS Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HLS Therapeutics in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" HLS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HLS, but not buy additional shares or sell existing shares. View HLS analyst ratings or view top-rated stocks. What is HLS Therapeutics' stock price target for 2024? 3 brokerages have issued 1-year price targets for HLS Therapeutics' shares. Their HLS share price targets range from C$5.00 to C$17.50. On average, they predict the company's share price to reach C$10.50 in the next twelve months. This suggests a possible upside of 188.5% from the stock's current price. View analysts price targets for HLS or view top-rated stocks among Wall Street analysts. How have HLS shares performed in 2023? HLS Therapeutics' stock was trading at C$9.83 on January 1st, 2023. Since then, HLS stock has decreased by 63.0% and is now trading at C$3.64. View the best growth stocks for 2023 here. When is HLS Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our HLS earnings forecast. How were HLS Therapeutics' earnings last quarter? HLS Therapeutics Inc. (TSE:HLS) issued its quarterly earnings data on Thursday, November, 9th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.12. The company earned $21.52 million during the quarter, compared to the consensus estimate of $21.97 million. HLS Therapeutics had a negative net margin of 45.41% and a negative trailing twelve-month return on equity of 24.49%. How often does HLS Therapeutics pay dividends? What is the dividend yield for HLS Therapeutics? HLS Therapeutics declared a quarterly dividend on Thursday, April 27th. Shareholders of record on Thursday, June 15th will be paid a dividend of 0.05 per share on Thursday, June 15th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 5.49%. The ex-dividend date is Thursday, April 27th. Read our dividend analysis for HLS. Is HLS Therapeutics a good dividend stock? HLS Therapeutics (TSE:HLS) pays an annual dividend of C$0.20 per share and currently has a dividend yield of 5.56%. HLS has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. Read our dividend analysis for HLS. What other stocks do shareholders of HLS Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other HLS Therapeutics investors own include Cargojet (CJT), Fairfax Financial (FFH), Fortis (FTS), Aurora Cannabis (ACB), Aphria (APHA), Alimentation Couche-Tard (ATD.B), BlackBerry (BB), BCE (BCE), Bank of Montreal (BMO) and Bank of Nova Scotia (BNS). How do I buy shares of HLS Therapeutics? Shares of HLS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:HLS) was last updated on 12/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HLS Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.